Paediatric-onset lymphomatoid papulosis: results of a multicentre retrospective cohort study on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG)
Open Access
- 10 April 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (2) , 233-242
Abstract
Background: Lymphomatoid papulosis (LyP) is a rare cutaneous T-cell lymphoproliferative disorder. Comprehensive data on LyP in the paediatric population are scarce. Objectives: To characterize the epidemiological, clinical, histopathological and prognostic features of paediatric LyP. Methods: This was a retrospective multicentre international cohort study that included 87 children and adolescents with LyP diagnosed between 1998 and 2022. Patients aged ≤ 18 years at disease onset were included. LyP diagnosis was made in each centre, based on clinicopathological correlation. Results: Eighty-seven patients from 12 centres were included. Mean age at disease onset was 7.0 years (range 3 months–18 years) with a male to female ratio of 2 : 1. Mean time between the onset of the first cutaneous lesions and diagnosis was 1.3 years (range 0–14). Initial misdiagnosis concerned 26% of patients. LyP was most often misdiagnosed as pityriasis lichenoides et varioliformis acuta, insect bites or mollusca contagiosa. Erythematous papules or papulonodules were the most frequent clinical presentation. Pruritus was specifically mentioned in 21% of patients. The main histological subtype was type A in 55% of cases. When analysed, monoclonal T-cell receptor rearrangement was found in 77% of skin biopsies. The overall survival rate was 100%, with follow-up at 5 years available for 33 patients and at 15 years for 8 patients. Associated haematological malignancy (HM) occurred in 10% of cases (n = 7/73), including four patients with mycosis fungoides, one with primary cutaneous anaplastic large cell lymphoma (ALCL), one with systemic ALCL and one with acute myeloid leukaemia. If we compared incidence rates of cancer with the world population aged 0–19 years from 2001 to 2010, we estimated a significantly higher risk of associated malignancy in general, occurring before the age of 19 years (incidence rate ratio 87.49, 95% confidence interval 86.01–88.99). Conclusions: We report epidemiological data from a large international cohort of children and adolescents with LyP. Overall, the disease prognosis is good, with excellent survival rates for all patients. Owing to an increased risk of associated HM, long-term follow-up should be recommended for patients with LyP.Keywords
Funding Information
- Promedica Stiftung (1406/M, 1412/M)
- Swiss Cancer Research Foundation (KFS-4243-08-2017)
- Swiss National Science Foundation (IZLIZ3_200253/1)
- University of Lausanne
This publication has 49 references indexed in Scilit:
- Clinicopathological Factors Associated with the Prognosis and Chronicity of Lymphomatoid Papulosis: A Retrospective Cohort StudyClinical Lymphoma Myeloma and Leukemia, 2022
- Mycosis Fungoides in Children and AdolescentsJAMA Dermatology, 2021
- Lymphomatoid papulosis in children and adolescents: A clinical and histopathologic retrospective cohortAnnals of Diagnostic Pathology, 2020
- Primary Cutaneous Lymphomas in Children and AdolescentsPediatric Blood & Cancer, 2016
- Lymphomatoid Papulosis in Children and Adolescents: A Systematic ReviewAmerican Journal of Clinical Dermatology, 2016
- Juvenile mycosis fungoides: Cutaneous T-cell lymphoma with frequent follicular involvementJournal of the American Academy of Dermatology, 2014
- In search of prognostic indicators for lymphomatoid papulosis: A retrospective study of 123 patientsJournal of the American Academy of Dermatology, 2012
- Cutaneous hematologic disorders in childrenPediatric Blood & Cancer, 2011
- Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patientsJournal of the American Academy of Dermatology, 2009
- Outcome in 34 patients with juvenile‐onset mycosis fungoidesCancer, 2003